Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ensitrelvir  COVID-19 treatment studies for Ensitrelvir  C19 studies: Ensitrelvir  Ensitrelvir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Improvement in sympt.. 9% Improvement Relative Risk Improvement in s.. (b) 17% Time to viral-, 250mg 32% Time to viral-, 125mg 44% c19early.org/en Mukae et al. jRCT2031210350 Ensitrelvir RCT EARLY Is early treatment with ensitrelvir beneficial for COVID-19? Double-blind RCT 227 patients in Japan (January - February 2022) Faster viral clearance with ensitrelvir (p=0.0001) Mukae et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac933 Favors ensitrelvir Favors control
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Mukae et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac933, jRCT2031210350
Mukae et al., Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a.., Clinical Infectious Diseases, doi:10.1093/cid/ciac933, jRCT2031210350
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 428 COVID-19 patients in Japan showing faster viral clearance and improved recovery with ensitrelvir.
relative improvement in symptom score, 9.2% better, RR 0.91, p = 0.28, treatment mean 5.42 (±3.7) n=116, control mean 4.92 (±3.25) n=111, 250mg, Table 2.
relative improvement in symptom score, 17.3% better, RR 0.83, p = 0.04, treatment mean 5.95 (±4.02) n=114, control mean 4.92 (±3.25) n=111, 125mg, Table 2.
time to viral-, 32.4% lower, relative time 0.68, p < 0.001, treatment 113, control 108, relative time to first negative viral titer, 250mg, Figure 3.
time to viral-, 44.2% lower, relative time 0.56, p < 0.001, treatment 113, control 108, relative time to first negative viral titer, 125mg, Figure 3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mukae et al., 7 Dec 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Japan, peer-reviewed, 11 authors, study period 2 January, 2022 - 9 February, 2022, trial jRCT2031210350.
Contact: takeki.uehara@shionogi.co.jp.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperEnsitrelvirAll
Abstract: Clinical Infectious Diseases SC RI PT RESEARCH ARTICLE Efficacy and safety of ensitrelvir in patients with mild-tomoderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study U Hiroshi Mukae1, Hiroshi Yotsuyanagi2, Norio Ohmagari3, Yohei Doi4,5, Hiroki Sakaguchi6, Takuhiro Sonoyama6, Genki Ichihashi6, Takao Sanaki7, Keiko Baba7, Yuko Tsuge6, Takeki Uehara6* 1 TE D M A N Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; 2The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 3Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; 4Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; 5Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan; 6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan; 7Pharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Japan EP Background. This phase 2b part of a randomized phase 2/3 study assessed the efficacy and safety of ensitrelvir for mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron epidemic. A CC —————————————————————————————————————— *Corresponding author: Takeki Uehara Drug Development and Regulatory Science Division, Shionogi & Co., Ltd. Address: 8F, Nissay Yodoyabashi East, 3-3-13 Imabashi, Chuo-ku, Osaka 541-0042, Japan Email: takeki.uehara@shionogi.co.jp © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com DOI: 10.1093/cid/ciac933 1 SC RI PT Methods. Patients were randomized (1:1:1) to orally receive ensitrelvir fumaric acid 125 mg (375 mg on day 1) or 250 mg (750 mg on day 1) or placebo once daily for 5 days. The co-primary endpoints were the change from baseline in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) titer on day 4 and time-weighted average change from baseline up to 120 hours in the total score of predefined 12 COVID-19 symptoms. Safety was assessed through adverse events. N U Results. A total of 341 patients (ensitrelvir 125 mg group, 114; ensitrelvir 250 mg group, 116; and placebo group, 111; male, 53.5%–64.9%; mean age, 35.3–37.3 years) were included in the efficacy analyses. The change from baseline in the SARS-CoV-2 titer on day 4 was significantly greater with both ensitrelvir doses than with placebo (differences from placebo: -0.41 log10 50% tissue-culture infectious dose/mL, P<0.0001 for both). The total score of the 12 COVID-19 symptoms did not show a significant difference between the ensitrelvir groups and placebo group. The time-weighted average change from baseline up to 120 hours was significantly greater with ensitrelvir versus placebo in several subtotal scores, including acute symptoms and respiratory symptoms. Most adverse events were mild in severity. A Conclusions. Ensitrelvir treatment demonstrated a..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit